Akari Therapeutics
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company based in London, United Kingdom, dedicated to developing and commercializing treatments for rare and orphan autoimmune and inflammatory diseases. The company's lead product candidate, Nomacopan, is a second-generation complement inhibitor that targets the complement component 5 (C5) and leukotriene B4 (LTB4) pathways, playing a crucial role in disease progression. Nomacopan is currently being evaluated in clinical trials for several conditions, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, bullous pemphigoid, and thrombotic microangiopathy. Akari Therapeutics is committed to addressing unmet medical needs in these areas through innovative therapeutic solutions.
Top Stages
1 past transactions
Peak Bio
Acquisition in 2024
Peak Bio is a clinical-stage biopharmaceutical company dedicated to the development of therapeutics aimed at addressing unmet medical needs in oncology, inflammation, and rare diseases. The company is focused on creating innovative drug solutions to improve patient outcomes in these therapeutic areas. By prioritizing the development of new treatments, Peak Bio seeks to make a significant impact on the healthcare landscape, particularly for conditions that currently lack effective therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.